Embedded Files
2025
2025
2024
2024
Victoria J. Morel, Jochen Rössler and Michele Bernasconi
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future.
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future.
Medicinal Research Review 2024: 44, 2730-2773
Andrea Timpanaro†, Caroline Piccand†, Dzhangar Dzhumashev, Stenija Anton‑Joseph3, Andrea Robbi, Janine Moser, Jochen Rössler and Michele Bernasconi
CD276‑CAR T cells and Dual‑CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
CD276‑CAR T cells and Dual‑CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
J Exp Clin Cancer Res 2024: 42, 293
Sofia Dominguez-Gil, Rita Sala, Victoria Judith Morel, Christophe Nguyen, Khaled El Cheikh, Alain Morère, Jean-Olivier Durand, Jochen Rössler, Michele Bernasconi, Frédérique Cunin and Magali Gary-Bobo
Rhabdomyosarcoma targeting with tuned porous silicon nanoparticles
Rhabdomyosarcoma targeting with tuned porous silicon nanoparticles
Nano Select 2024: 2400004
2023
2023
Dzhangar Dzhumashev, Stenija Anton-Joseph, Victoria J Morel, Andrea Timpanaro, Gregor Bordon, Caroline Piccand, Simone Aleandri, Paola Luciani, Jochen Rössler, Michele Bernasconi
Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells
Eur J Pharm Biopharm 2023: 194, 49-61
Andrea Timpanaro, Caroline Piccand, Anne-Christine Uldry, Peter Karl Bode, Dzhangar Dzhumashev, Rita Sala, Manfred Heller, Jochen Rössler and Michele Bernasconi
Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Int J Mol Sci 2023: 24, 2601
2022
2022
Dzhangar Dzhumashev, Andrea Timpanaro, Safa Ali, Andrea J. De Micheli, Kamel Mamchaoui, Ilaria Cascone, Jochen Rössler and Michele Bernasconi
Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma.
Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma.
2020
2020
Nagjie Alijaj, Sandrine Moutel, Zelia L. Gouveia, Maxim Gray, Maurizio Roveri, Dzhangar Dzhumashev, Florian Weber, Gianmarco Meier, Paola Luciani, Jochen K. Rössler, Beat W. Schäfer, Franck Perez and Michele Bernasconi
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma.
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma.
Morgane Daurat, Christophe Nguyen, Sofia Dominguez Gil, Vincent Sol, Vincent Chaleix, Clarence Charnay, Laurence Raehm, Khaled El Cheikh, Alain Morère, Michele Bernasconi, Andrea Timpanaro, Marcel Garcia, Frédérique Cunin, Jochen Roessler, Jean-Olivier Durand and Magali Gary-Bobo
The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics.
The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics.
2019
2019
Michele Bernasconi, Dzhangar Dzhumashev, Andrea Timpanaro and Jochen Rössler
Michele Bernasconi, Dzhangar Dzhumashev, Andrea Timpanaro and Jochen Rössler
Targeted therapies for rhabdomyosarcoma.
Targeted therapies for rhabdomyosarcoma.
Schweizer Krebsbulletin 2019: 39, 129-133 pdf
Page updated
Google Sites
Report abuse